HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia.

Abstract
This study aimed at determining the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction. Patients were enrolled into relapse trials ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Münster) 90 and 96. The prevalence of p16(INK4a) and p15(INK4b) homozygous deletions was 35% (44 of 125) and 30% (38 of 125), respectively. A highly significant association of both gene deletions was found with the 2 major adverse prognostic factors known for relapsed childhood ALL: T-cell immunophenotype and first remission duration. There was no correlation between INK4 deletions and probability of event-free survival. These findings argue against an independent prognostic role of INK4 deletions in relapsed childhood ALL.
AuthorsHagen Graf Einsiedel, Tillmann Taube, Reinhard Hartmann, Sven Wellmann, Georg Seifert, Günter Henze, Karl Seeger
JournalBlood (Blood) Vol. 99 Issue 12 Pg. 4629-31 (Jun 15 2002) ISSN: 0006-4971 [Print] United States
PMID12036898 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CDKN2B protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Proteins
Topics
  • Bone Marrow Cells (pathology)
  • Cell Cycle Proteins (genetics)
  • Child
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16 (genetics)
  • Disease-Free Survival
  • Female
  • Gene Deletion
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (epidemiology, genetics, pathology)
  • Prevalence
  • Prognosis
  • Recurrence
  • Retrospective Studies
  • Survival Analysis
  • Tumor Suppressor Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: